{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:15:34Z","timestamp":1793772934058,"version":"4.6.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009543","name":"Pontificia Universidad Javeriana","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Suministros Cl\u00ednicos ISLA S.A.S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1038\/s41434-022-00344-3","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T02:03:35Z","timestamp":1652839415000},"page":"107-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficient CRISPR\/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-1986","authenticated-orcid":false,"given":"Andr\u00e9s Felipe","family":"Leal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-1173","authenticated-orcid":false,"given":"Carlos Javier","family":"Alm\u00e9ciga-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"344_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21041517","volume":"21","author":"K Sawamoto","year":"2020","unstructured":"Sawamoto K, \u00c1lvarez Gonz\u00e1lez JV, Piechnik M, Otero FJ, Couce ML, Suzuki Y, et al. Mucopolysaccharidosis IVA: diagnosis, treatment, and management. Int J Mol Sci. 2020;21:1\u201326.","journal-title":"Int J Mol Sci"},{"key":"344_CR2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jmb.2012.08.020","volume":"423","author":"Y Rivera-Col\u00f3n","year":"2012","unstructured":"Rivera-Col\u00f3n Y, Schutsky EK, Kita AZ, Garman SC. The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A. J Mol Biol. 2012;423:736\u201351.","journal-title":"J Mol Biol"},{"key":"344_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diagnostics11020273","volume":"11","author":"B \u00c7elik","year":"2021","unstructured":"\u00c7elik B, Tomatsu SC, Tomatsu S, Khan SA. Epidemiology of Mucopolysaccharidoses update. Diagnostics. 2021;11:1\u201337.","journal-title":"Diagnostics"},{"key":"344_CR4","first-page":"602","volume":"32","author":"AMG-RR G\u00f3mez","year":"2012","unstructured":"G\u00f3mez AMG-RR, Su\u00e1rez-Obando, F. Estimation of the mucopolysaccharidoses frequencies and cluster analysis in the Colombian orovinces of Cundinamarca and Boyac\u00e1. Biomedica. 2012;32:602\u20139.","journal-title":"Biomedica"},{"key":"344_CR5","unstructured":"Sistema de Vigilancia en Salud Pu\u0301blica (Sivigila). Enfermedades hu\u00e9rfanas\u2014raras, Colombia, periodo epidemiolo\u0301gico I 2021. In: Instituto Nacional de Salud, 2021. pp 1\u20138."},{"key":"344_CR6","doi-asserted-by":"publisher","first-page":"e03635","DOI":"10.1016\/j.heliyon.2020.e03635","volume":"6","author":"MA Puentes-Tellez","year":"2020","unstructured":"Puentes-Tellez MA, Lerma-Barbosa PA, Garzon-Jaramillo RG, Suarez DA, Espejo-Mojica AJ, Guevara JM, et al. A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia. Heliyon. 2020;6:e03635.","journal-title":"Heliyon"},{"key":"344_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01675-x","volume":"16","author":"M Cleary","year":"2021","unstructured":"Cleary M, Davison J, Gould R, Geberhiwot T, Hughes D, Mercer J, et al. Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England. Orphanet J Rare Dis. 2021;16:38.","journal-title":"Orphanet J Rare Dis"},{"key":"344_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00109-020-01935-6","volume":"98","author":"AF Leal","year":"2020","unstructured":"Leal AF, Espejo-Mojica AJ, S\u00e1nchez OF, Ram\u00edrez CM, Reyes LH, Cruz JC, et al. Lysosomal storage diseases: current therapies and future alternatives. J Mol Med. 2020;98:931\u201346.","journal-title":"J Mol Med"},{"key":"344_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1074-9","volume":"14","author":"MU Akyol","year":"2019","unstructured":"Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, et al. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14:137.","journal-title":"Orphanet J Rare Dis"},{"key":"344_CR10","first-page":"143","volume":"16","author":"CLCC Lee","year":"2022","unstructured":"Lee CLCC, Chiu HC, Tu RY, Lo YT, Chang YH, Lin SP, et al. Clinical utility of elosulfase alfa in the treatment of morquio A syndrome. Drug Des Dev Ther. 2022;16:143\u201354.","journal-title":"Drug Des Dev Ther"},{"key":"344_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40265-019-01147-4","volume":"79","author":"K Sawamoto","year":"2019","unstructured":"Sawamoto K, Stapleton M, Almeciga-Diaz CJ, Espejo-Mojica AJ, Losada JC, Suarez DA, et al. Therapeutic options for mucopolysaccharidoses: current and emerging treatments. Drugs. 2019;79:1103\u201334.","journal-title":"Drugs"},{"key":"344_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ymgmr.2017.04.005","volume":"11","author":"B Donida","year":"2017","unstructured":"Donida B, Marchetti DP, Jacques CED, Ribas G, Deon M, Manini P, et al. Oxidative profile exhibited by Mucopolysaccharidosis type IVA patients at diagnosis: increased keratan urinary levels. Mol Genet Metab Rep. 2017;11:46\u201353.","journal-title":"Mol Genet Metab Rep"},{"key":"344_CR13","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.bbadis.2015.02.004","volume":"1852","author":"B Donida","year":"2015","unstructured":"Donida B, Marchetti DP, Biancini GB, Deon M, Manini PR, da Rosa HT, et al. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochim Biophys Acta. 2015;1852:1012\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"344_CR14","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.clinthera.2014.11.005","volume":"37","author":"B Schweighardt","year":"2015","unstructured":"Schweighardt B, Tompkins T, Lau K, Jesaitis L, Qi Y, Musson DG, et al. Immunogenicity of Elosulfase Alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase III trial. Clin Ther. 2015;37:1012\u201321. e6","journal-title":"Clin Ther"},{"key":"344_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.clinthera.2016.11.017","volume":"39","author":"B Long","year":"2017","unstructured":"Long B, Tompkins T, Decker C, Jesaitis L, Khan S, Slasor P, et al. Long-term immunogenicity of Elosulfase Alfa in the treatment of Morquio a syndrome: results from MOR-005, a phase III extension study. Clin Ther. 2017;39:118\u201329. e3","journal-title":"Clin Ther"},{"key":"344_CR16","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1021\/acsmedchemlett.0c00042","volume":"11","author":"S Olarte-Avellaneda","year":"2020","unstructured":"Olarte-Avellaneda S, Cepeda Del Castillo J, Rojas-Rodriguez AF, S\u00e1nchez O, Rodr\u00edguez-L\u00f3pez A, Su\u00e1rez Garc\u00eda DA, et al. Bromocriptine as a novel pharmacological chaperone for mucopolysaccharidosis IV A. ACS Med Chem Lett. 2020;11:1377\u201385.","journal-title":"ACS Med Chem Lett"},{"key":"344_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/ijms21010232","volume":"21","author":"JC Losada D\u00edaz","year":"2020","unstructured":"Losada D\u00edaz JC, Cepeda del Castillo J, Rodriguez-L\u00f3pez EA, Alm\u00e9ciga-D\u00edaz CJ. Advances in the development of pharmacological chaperones for the mucopolysaccharidoses. Int J Mol Sci. 2020;21:232.","journal-title":"Int J Mol Sci."},{"key":"344_CR18","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1021\/acs.jmedchem.9b00428","volume":"62","author":"CJ Almeciga-Diaz","year":"2019","unstructured":"Almeciga-Diaz CJ, Hidalgo OA, Olarte-Avellaneda S, Rodriguez-Lopez A, Guzman E, Garzon R, et al. Identification of ezetimibe and pranlukast as pharmacological chaperones for the treatment of the rare disease mucopolysaccharidosis type IVA. J Med Chem. 2019;62:6175\u201389.","journal-title":"J Med Chem."},{"key":"344_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21020500","volume":"21","author":"E Poletto","year":"2020","unstructured":"Poletto E, Baldo G, Gomez-Ospina N. Genome editing for mucopolysaccharidoses. Int J Mol Sci. 2020;21:1\u201320.","journal-title":"Int J Mol Sci"},{"key":"344_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41434-019-0086-3","volume":"27","author":"CJ Alm\u00e9ciga-Diaz","year":"2020","unstructured":"Alm\u00e9ciga-Diaz CJ, Barrera LA. Design and applications of gene therapy vectors for mucopolysaccharidosis in Colombia. Gene Ther. 2020;27:104\u20137.","journal-title":"Gene Ther"},{"key":"344_CR21","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1093\/hmg\/ddv457","volume":"25","author":"A Biffi","year":"2016","unstructured":"Biffi A. Gene therapy for lysosomal storage disorders: a good start. Hum Mol Genet. 2016;25:R65\u201375.","journal-title":"Hum Mol Genet"},{"key":"344_CR22","doi-asserted-by":"publisher","first-page":"145527","DOI":"10.1016\/j.gene.2021.145527","volume":"780","author":"MA Puentes-Tellez","year":"2021","unstructured":"Puentes-Tellez MA, S\u00e1nchez OF, Rojas-Rodriguez F, Benincore-Fl\u00f3rez E, Barbosa H, Alm\u00e9ciga D\u00edaz CJ. Evaluation of HIV-1 derived lentiviral vectors as transductors of Mucopolysaccharidosis type IV a fibroblasts. Gene. 2021;780:145527.","journal-title":"Gene"},{"key":"344_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41390-018-0095-8","volume":"84","author":"CJ Alm\u00e9ciga-D\u00edaz","year":"2018","unstructured":"Alm\u00e9ciga-D\u00edaz CJ, Monta\u00f1o AM, Barrera LA, Tomatsu S. Tailoring the AAV2 capsid vector for bone-targeting. Pediatr Res. 2018;84:545\u201351.","journal-title":"Pediatr Res"},{"key":"344_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.7705\/biomedica.v28i3.85","volume":"28","author":"MA Gutierrez","year":"2008","unstructured":"Gutierrez MA, Garcia-Vallejo F, Tomatsu S, Ceron F, Almeciga-Diaz CJ, Dominguez MC, et al. Construction of an adenoassociated virus-derived expression vector to correct the genetic defect in Morquio A disease. Biomedica. 2008;28:448\u201359.","journal-title":"Biomedica"},{"key":"344_CR25","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1111\/j.1742-4658.2010.07769.x","volume":"277","author":"C Alm\u00e9ciga-D\u00edaz","year":"2010","unstructured":"Alm\u00e9ciga-D\u00edaz C, Monta\u00f1o AM, Tomatsu S, Barrera L. Adeno-associated virus gene transfer on Morquio A: effect of promoters and sulfatase-modifying factor 1. FEBS J. 2010;277:3608\u201319.","journal-title":"FEBS J"},{"key":"344_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.omtm.2020.05.015","volume":"18","author":"K Sawamoto","year":"2020","unstructured":"Sawamoto K, Karumuthil-Melethil S, Khan S, Stapleton M, Bruder JT, Danos O, et al. Liver-targeted AAV8 gene therapy ameliorates skeletal and cardiovascular pathology in a Mucopolysaccharidosis IVA murine model. Mol Ther Methods Clin Dev. 2020;18:50\u201361.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"344_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25697-y","volume":"12","author":"J Bertolin","year":"2021","unstructured":"Bertolin J, S\u00e1nchez V, Ribera A, Ja\u00e9n ML, Garcia M, Pujol A, et al. Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy. Nat Commun. 2021;12:5343.","journal-title":"Nat Commun"},{"key":"344_CR28","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32:1529\u201341.","journal-title":"Leukemia"},{"key":"344_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","volume":"120","author":"SR Choudhury","year":"2017","unstructured":"Choudhury SR, Hudry E, Maguire CA, Sena-Esteves M, Breakefield XO, Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology. 2017;120:63\u201380.","journal-title":"Neuropharmacology"},{"key":"344_CR30","doi-asserted-by":"publisher","first-page":"12267","DOI":"10.1002\/jcp.27972","volume":"234","author":"A Karimian","year":"2019","unstructured":"Karimian A, Azizian K, Parsian H, Rafieian S, Shafiei-Irannejad V, Kheyrollah M, et al. CRISPR\/Cas9 technology as a potent molecular tool for gene therapy. J Cell Physiol. 2019;234:12267\u201377.","journal-title":"J Cell Physiol"},{"key":"344_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang F, Doudna JA. CRISPR-Cas9 structures and mechanisms. Annu Rev Biophys. 2017;46:505\u201329.","journal-title":"Annu Rev Biophys"},{"key":"344_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep24356","volume":"6","author":"TW Chiang","year":"2016","unstructured":"Chiang TW, le Sage C, Larrieu D, Demir M, Jackson SP. CRISPR-Cas9(D10A) nickase-based genotypic and phenotypic screening to enhance genome editing. Sci Rep. 2016;6:24356.","journal-title":"Sci Rep"},{"key":"344_CR33","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3389\/fphar.2018.00749","volume":"9","author":"LOW Wilson","year":"2018","unstructured":"Wilson LOW, O\u2019Brien AR, Bauer DC. The current state and future of CRISPR-Cas9 gRNA design tools. Front Pharmacol. 2018;9:749.","journal-title":"Front Pharmacol"},{"key":"344_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41434-019-0113-4","volume":"27","author":"RS Schuh","year":"2020","unstructured":"Schuh RS, Gonzalez EA, Tavares AMV, Seolin BG, Elias LS, Vera LNP, et al. Neonatal nonviral gene editing with the CRISPR\/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice. Gene Ther. 2020;27:74\u201384.","journal-title":"Gene Ther"},{"key":"344_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2018.08.031","volume":"288","author":"RS Schuh","year":"2018","unstructured":"Schuh RS, Poletto E, Pasqualim G, Tavares AMV, Meyer FS, Gonzalez EA, et al. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR\/Cas9 system. J Control Release. 2018;288:23\u201333.","journal-title":"J Control Release"},{"key":"344_CR36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejpb.2017.10.017","volume":"122","author":"RS Schuh","year":"2018","unstructured":"Schuh RS, de CTG, Giugliani R, Matte U, Baldo G, Teixeira HF. Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR\/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers. Eur J Pharm Biopharm. 2018;122:158\u201366.","journal-title":"Eur J Pharm Biopharm."},{"key":"344_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41434-019-0120-5","volume":"27","author":"L Ou","year":"2020","unstructured":"Ou L, Przybilla MJ, T\u0103b\u0103ran AF, Overn P, O\u2019Sullivan MG, Jiang X, et al. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases. Gene Ther. 2020;27:226\u201336.","journal-title":"Gene Ther"},{"key":"344_CR38","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ajmg.c.31936","volume":"187","author":"H Pachajoa","year":"2021","unstructured":"Pachajoa H, Acosta MA, Alm\u00e9ciga-D\u00edaz CJ, Ariza Y, Diaz-Ordo\u00f1ez L, Caicedo-Herrera G, et al. Molecular characterization of mucopolysaccharidosis type IVA patients in the Andean region of Colombia. Am J Med Genet C Semin Med Genet. 2021;187:388\u201395.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"344_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-019-1760-2","volume":"9","author":"AP Uniyal","year":"2019","unstructured":"Uniyal AP, Mansotra K, Yadav SK, Kumar V. An overview of designing and selection of sgRNAs for precise genome editing by the CRISPR-Cas9 system in plants. 3 Biotech. 2019;9:223.","journal-title":"3 Biotech"},{"key":"344_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ymgme.2007.01.004","volume":"91","author":"S Tomatsu","year":"2007","unstructured":"Tomatsu S, Montano AM, Gutierrez M, Grubb JH, Oikawa H, Dung VC, et al. Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase. Mol Genet Metab. 2007;91:69\u201378.","journal-title":"Mol Genet Metab"},{"key":"344_CR41","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42:e168.","journal-title":"Nucleic Acids Res"},{"key":"344_CR42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/elps.201100335","volume":"33","author":"PS Aranda","year":"2012","unstructured":"Aranda PS, LaJoie DM, Jorcyk CL. Bleach gel: a simple agarose gel for analyzing RNA quality. Electrophoresis. 2012;33:366\u20139.","journal-title":"Electrophoresis"},{"key":"344_CR43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0009-8981(90)90339-T","volume":"187","author":"OP van Diggelen","year":"1990","unstructured":"van Diggelen OP, Zhao H, Kleijer WJ, Janse HC, Poorthuis BJ, van Pelt J, et al. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A). Clin Chim Acta. 1990;187:131\u20139.","journal-title":"Clin Chim Acta"},{"key":"344_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.gene.2018.08.004","volume":"678","author":"TG de Carvalho","year":"2018","unstructured":"de Carvalho TG, Schuh R, Pasqualim G, Pellenz FM, Filippi-Chiela EC, Giugliani R, et al. CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts. Gene. 2018;678:33\u201337.","journal-title":"Gene"},{"key":"344_CR45","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"344_CR46","doi-asserted-by":"publisher","first-page":"5558618","DOI":"10.1155\/2021\/5558618","volume":"2021","author":"YW Lee","year":"2021","unstructured":"Lee YW, Cherng YG, Yang ST, Liu SH, Chen TL, Chen RM. Hypoxia induced by cobalt chloride triggers autophagic apoptosis of human and mouse drug-resistant glioblastoma cells through targeting the PI3K-AKT-mTOR signaling pathway. Oxid Med Cell Longev. 2021;2021:5558618.","journal-title":"Oxid Med Cell Longev"},{"key":"344_CR47","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/jat.3749","volume":"39","author":"J Mu\u00f1oz-S\u00e1nchez","year":"2019","unstructured":"Mu\u00f1oz-S\u00e1nchez J, Ch\u00e1nez-C\u00e1rdenas ME. The use of cobalt chloride as a chemical hypoxia model. J Appl Toxicol. 2019;39:556\u201370.","journal-title":"J Appl Toxicol"},{"key":"344_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/science.aan4672","volume":"359","author":"CE Dunbar","year":"2018","unstructured":"Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359:1\u201310.","journal-title":"Science"},{"key":"344_CR49","doi-asserted-by":"publisher","first-page":"100455","DOI":"10.1016\/j.ymgmr.2019.100455","volume":"19","author":"H Fujitsuka","year":"2019","unstructured":"Fujitsuka H, Sawamoto K, Peracha H, Mason RW, Mackenzie W, Kobayashi H, et al. Biomarkers in patients with mucopolysaccharidosis type II and IV. Mol Genet Metab Rep. 2019;19:100455.","journal-title":"Mol Genet Metab Rep"},{"key":"344_CR50","first-page":"S72","volume":"135","author":"AF Leal","year":"2022","unstructured":"Leal AF, Espejo-Mojica AJ, Alme\u0301ciga-Di\u0301az CJ. Genome editing on GM2 gangliosidoses fibroblasts using CRISPR\/nCas9. Mol Genet Metab. 2022;135:S72.","journal-title":"Mol Genet Metab"},{"key":"344_CR51","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/bit.20566","volume":"91","author":"J Jones","year":"2005","unstructured":"Jones J, Nivitchanyong T, Giblin C, Ciccarone V, Judd D, Gorfien S, et al. Optimization of tetracycline-responsive recombinant protein production and effect on cell growth and ER stress in mammalian cells. Biotechnol Bioeng. 2005;91:722\u201332.","journal-title":"Biotechnol Bioeng"},{"key":"344_CR52","doi-asserted-by":"publisher","first-page":"102620","DOI":"10.1016\/j.plasmid.2022.102620","volume":"119-120","author":"I Tossolini","year":"2022","unstructured":"Tossolini I, Gugliotta A, L\u00f3pez D\u00edaz F, Kratje R, Prieto C. Screening of CHO-K1 endogenous promoters for expressing recombinant proteins in mammalian cell cultures. Plasmid. 2022;119-120:102620.","journal-title":"Plasmid"},{"key":"344_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cellsig.2015.10.013","volume":"28","author":"E Borkham-Kamphorst","year":"2016","unstructured":"Borkham-Kamphorst E, Steffen BT, Van de Leur E, Haas U, Tihaa L, Friedman SL, et al. CCN1\/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis. Cell Signal. 2016;28:34\u201342.","journal-title":"Cell Signal"},{"key":"344_CR54","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1111\/1440-1681.12453","volume":"42","author":"BD Chen","year":"2015","unstructured":"Chen BD, He CH, Chen XC, Pan S, Liu F, Ma X, et al. Targeting transgene to the heart and liver with AAV9 by different promoters. Clin Exp Pharmacol Physiol. 2015;42:1108\u201317.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"344_CR55","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/humc.2013.147","volume":"24","author":"TJ Conlon","year":"2013","unstructured":"Conlon TJ, Erger K, Porvasnik S, Cossette T, Roberts C, Combee L, et al. Preclinical toxicology and biodistribution studies of recombinant adeno-associated virus 1 human acid alpha-glucosidase. Hum Gene Ther Clin Dev. 2013;24:127\u201333.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"344_CR56","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.3892\/mmr.2017.6235","volume":"15","author":"Q Chen","year":"2017","unstructured":"Chen Q, Zhai H, Li X, Ma Y, Chen B, Liu F, et al. Recombinant adeno-associated virus serotype 9 in a mouse model of atherosclerosis: Determination of the optimal expression time in vivo. Mol Med Rep. 2017;15:2090\u20136.","journal-title":"Mol Med Rep"},{"key":"344_CR57","doi-asserted-by":"publisher","first-page":"e67446","DOI":"10.1371\/journal.pone.0067446","volume":"8","author":"L Geng","year":"2013","unstructured":"Geng L, Gao Y, Chen X, Hou S, Zhan CG, Radic Z, et al. Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity. PLoS One. 2013;8:e67446.","journal-title":"PLoS One"},{"key":"344_CR58","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11095-018-2503-5","volume":"35","author":"RS Schuh","year":"2018","unstructured":"Schuh RS, Bidone J, Poletto E, Pinheiro CV, Pasqualim G, de Carvalho TG, et al. Nasal administration of cationic nanoemulsions as nucleic acids delivery systems aiming at mucopolysaccharidosis type I gene therapy. Pharm Res. 2018;35:221.","journal-title":"Pharm Res"},{"key":"344_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.omtm.2021.11.007","volume":"24","author":"E Rintz","year":"2022","unstructured":"Rintz E, Higuchi T, Kobayashi H, Galileo DS, Wegrzyn G, Tomatsu S. Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases. Mol Ther Methods Clin Dev. 2022;24:71\u201387.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"344_CR60","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1111\/j.1742-4658.2010.07769.x","volume":"277","author":"CJ Alm\u00e9ciga-D\u00edaz","year":"2010","unstructured":"Alm\u00e9ciga-D\u00edaz CJ, Monta\u00f1o AM, Tomatsu S, Barrera LA. Adeno-associated virus gene transfer in Morquio A disease\u2014effect of promoters and sulfatase-modifying factor 1. FEBS J. 2010;277:3608\u201319.","journal-title":"FEBS J"},{"key":"344_CR61","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1007\/s11033-008-9392-3","volume":"36","author":"C Alm\u00e9ciga-D\u00edaz","year":"2009","unstructured":"Alm\u00e9ciga-D\u00edaz C, Rueda-Paramo M, Espejo A, Echeverri O, Monta\u00f1o A, Tomatsu S, et al. Effect of Elongation Factor 1\u03b1 promoter and SUMF1 over in-vitro expression of N-acetylgalactosamine-6-sulfate sulfatase. Mol Biol Rep. 2009;36:1863\u201370.","journal-title":"Mol Biol Rep"},{"key":"344_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02013-7","volume":"7","author":"A Satomura","year":"2017","unstructured":"Satomura A, Nishioka R, Mori H, Sato K, Kuroda K, Ueda M. Precise genome-wide base editing by the CRISPR Nickase system in yeast. Sci Rep. 2017;7:2095.","journal-title":"Sci Rep"},{"key":"344_CR63","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1534\/g3.118.200758","volume":"9","author":"XA Ge","year":"2019","unstructured":"Ge XA, Hunter CP. Efficient homologous recombination in mice using long single stranded DNA and CRISPR Cas9 nickase. G3. 2019;9:281\u20136.","journal-title":"G3"},{"key":"344_CR64","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s13238-014-0032-5","volume":"5","author":"Z Rong","year":"2014","unstructured":"Rong Z, Zhu S, Xu Y, Fu X. Homologous recombination in human embryonic stem cells using CRISPR\/Cas9 nickase and a long DNA donor template. Protein Cell. 2014;5:258\u201360.","journal-title":"Protein Cell"},{"key":"344_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diseases7030047","volume":"7","author":"CL Christensen","year":"2019","unstructured":"Christensen CL, Ashmead RE, Choy FYM. Cell and gene therapies for mucopolysaccharidoses: base editing and therapeutic delivery to the CNS. Diseases. 2019;7:1\u201327.","journal-title":"Diseases"},{"key":"344_CR66","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ymgme.2014.03.004","volume":"112","author":"A Morrone","year":"2014","unstructured":"Morrone A, Tylee KL, Al-Sayed M, Brusius-Facchin AC, Caciotti A, Church HJ, et al. Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations. Mol Genet Metab. 2014;112:160\u201370.","journal-title":"Mol Genet Metab"},{"key":"344_CR67","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ymgme.2016.11.007","volume":"120","author":"S Khan","year":"2017","unstructured":"Khan S, Alm\u00e9ciga-D\u00edaz CJ, Sawamoto K, Mackenzie WG, Theroux MC, Pizarro C, et al. Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab. 2017;120:78\u201395.","journal-title":"Mol Genet Metab"},{"key":"344_CR68","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/humu.24270","volume":"42","author":"A Zanetti","year":"2021","unstructured":"Zanetti A, D\u2019Avanzo F, AlSayed M, Brusius-Facchin AC, Chien YH, Giugliani R, et al. Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): a review and classification of GALNS gene variants and reporting of 68 novel variants. Hum Mutat. 2021;42:1384\u201398.","journal-title":"Hum Mutat"},{"key":"344_CR69","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1006\/geno.1994.1132","volume":"20","author":"Y Nakashima","year":"1994","unstructured":"Nakashima Y, Tomatsu S, Hori T, Fukuda S, Sukegawa K, Kondo N, et al. Mucopolysaccharidosis IV A: molecular cloning of the human N-acetylgalactosamine-6-sulfatase gene (GALNS) and analysis of the 5\u2019-flanking region. Genomics. 1994;20:99\u2013104.","journal-title":"Genomics"},{"key":"344_CR70","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/fluids6090309","volume":"6","author":"KA Giraldo","year":"2021","unstructured":"Giraldo KA, Bermudez JS, Torres CE, Reyes LH, Osma JF, Cruz JC. Microfluidics for multiphase mixing and liposomal encapsulation of nanobioconjugates: passive vs. acoustic systems. Fluids. 2021;6:309.","journal-title":"Fluids"},{"key":"344_CR71","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1021\/acsbiomaterials.9b01214","volume":"6","author":"N Lopez-Barbosa","year":"2020","unstructured":"Lopez-Barbosa N, Suarez-Arnedo A, Cifuentes J, Gonzalez BAF, Silvera BCA, Osma JF, et al. Magnetite-OmpA nanobioconjugates as cell-penetrating vehicles with endosomal escape abilities. ACS Biomater Sci Eng. 2020;6:415\u201324.","journal-title":"ACS Biomater Sci Eng"},{"key":"344_CR72","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/mi11121050","volume":"11","author":"A Aranguren","year":"2020","unstructured":"Aranguren A, Torres CE, Mu\u00f1oz-Camargo C, Osma JF, Cruz JC. Synthesis of nanoscale liposomes via low-cost microfluidic systems. Micromachines. 2020;11:1050.","journal-title":"Micromachines"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00344-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T06:32:31Z","timestamp":1676529151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00344-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":72,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1038\/s41434-022-00344-3","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"12 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This project was approved by the Research and Ethics Committee of the Faculty of Science at Pontificia Universidad Javeriana.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}